According to a new study led by researchers at NYU Grossman School of Medicine and its Laura and Isaac Perlmutter Cancer Center, a combination of experimental drugs has shown to extend survival…
Category: Lung Cancer Drugs
Get an ideas about the lung cancer treatment drugs, here we provide only information about drugs not to advice them to take without proper doctor guideline. For information about lung cancer drugs browse.
FDA Approves First Targeted Therapy for Lung Cancer with Specific Genetic Mutation
The U.S. Food and Drug Administration has approved Lumakras (sotorasib) as first treatment for non-small cell lung cancer patients whose tumors have specific type of genetic mutation called KRAS G12C. It is…
Topotecan–Berzosertib Combination Effective for SCLC Treatment
Researchers all over the world are continuously been working towards finding effective treatments and therapies for lung cancer. There are widely two types of lung cancer: small cell lung cancer (SCLC) and…
FDA Approves Libtayo as Monotherapy for Advanced NSCLC
Lung cancer is one of the leading causes of cancer-related deaths worldwide. In the year 2020, an estimated 225,000 new cases were diagnosed in the United States. Also, approximately 84% of all…
New Study Identifies Drug to Boost Lung Cancer Survival Rates
A new study has found that a newly approved drug for leading form of cancer, lung cancer works to improve patient survival rate. The immunotherapy drug is called Tecentriq or atezolizumab. It…
Korean Study Examined Three-Drug Combo to Reduce Lung Cancer Risk
The combined use of aspirin, statins and metformin is associated with reduced risk of lung cancer, according to a study published in the Journal of Thoracic Oncology. The purpose behind the study…
NICE now recommends AstraZeneca’s Tagrisso for Lung Cancer Treatment
The National Institute of Health and Care Excellence (NICE) has announced the recommendation of Tagrisso (osimertinib) for routine use in two new lung cancer indications. The first indication is in the locally…
FDA Approves Gavreto for Metastatic Non-Small Cell Lung Cancer
The Food and Drug Administration (FDA) has approved Gavreto (pralsetinib) for treatment of patients with metastatic non-small cell lung cancer (NSCLC). Blueprint Medicines Corporation is a precision therapy company focused on genomically…